{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:25:32Z","timestamp":1790007932843,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:00:00Z","timestamp":1382400000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00228-013-1600-y","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T01:13:22Z","timestamp":1382318002000},"page":"127-134","source":"Crossref","is-referenced-by-count":149,"title":["Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis"],"prefix":"10.1007","volume":"70","author":[{"given":"G.","family":"D\u00e9sam\u00e9ricq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Schurhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Meary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sz\u00f6ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Macquin-Mavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Bachoud-L\u00e9vi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Maison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,22]]},"reference":[{"key":"1600_CR1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","volume":"12","author":"RW Heinrichs","year":"1998","unstructured":"Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426\u2013445","journal-title":"Neuropsychology"},{"key":"1600_CR2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.biopsych.2005.01.003","volume":"57","author":"RSE Keefe","year":"2005","unstructured":"Keefe RSE, Eesley CE, Poe MP (2005) Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 57:688\u2013691. doi: 10.1016\/j.biopsych.2005.01.003","journal-title":"Biol Psychiatry"},{"key":"1600_CR3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/appi.ajp.157.4.549","volume":"157","author":"RM Bilder","year":"2000","unstructured":"Bilder RM, Goldman RS, Robinson D et al (2000) Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 157:549\u2013559","journal-title":"Am J Psychiatry"},{"key":"1600_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","volume":"153","author":"MF Green","year":"1996","unstructured":"Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321\u2013330","journal-title":"Am J Psychiatry"},{"key":"1600_CR5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","volume":"26","author":"MF Green","year":"2000","unstructured":"Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u201cright stuff\u201d? Schizophr Bull 26:119\u2013136","journal-title":"Schizophr Bull"},{"key":"1600_CR6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1176\/ajp.155.8.1080","volume":"155","author":"PD Harvey","year":"1998","unstructured":"Harvey PD, Howanitz E, Parrella M et al (1998) Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 155:1080\u20131086","journal-title":"Am J Psychiatry"},{"key":"1600_CR7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4088\/JCP.v65n0312","volume":"65","author":"PD Harvey","year":"2004","unstructured":"Harvey PD, Green MF, Keefe RSE, Velligan DI (2004) Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 65:361\u2013372","journal-title":"J Clin Psychiatry"},{"key":"1600_CR8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.1077141","volume":"299","author":"SE Hyman","year":"2003","unstructured":"Hyman SE, Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science 299:350\u2013351. doi: 10.1126\/science.1077141","journal-title":"Science"},{"key":"1600_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","volume":"25","author":"RS Keefe","year":"1999","unstructured":"Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201\u2013222","journal-title":"Schizophr Bull"},{"key":"1600_CR10","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","volume":"55","author":"AL Mishara","year":"2004","unstructured":"Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55:1013\u20131022. doi: 10.1016\/j.biopsych.2004.01.027","journal-title":"Biol Psychiatry"},{"key":"1600_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","volume":"8","author":"ND Woodward","year":"2005","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457\u2013472. doi: 10.1017\/S146114570500516X","journal-title":"Int J Neuropsychopharmacol"},{"key":"1600_CR12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0269881105057002","volume":"20","author":"AE Thornton","year":"2006","unstructured":"Thornton AE, Van Snellenberg JX, Sepehry AA, Honer W (2006) The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol (Oxford) 20:335\u2013346. doi: 10.1177\/0269881105057002","journal-title":"J Psychopharmacol (Oxford)"},{"key":"1600_CR13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","volume":"166","author":"M Davidson","year":"2009","unstructured":"Davidson M, Galderisi S, Weiser M et al (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166:675\u2013682. doi: 10.1176\/appi.ajp.2008.08060806","journal-title":"Am J Psychiatry"},{"key":"1600_CR14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","volume":"64","author":"RSE Keefe","year":"2007","unstructured":"Keefe RSE, Bilder RM, Davis SM et al (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633\u2013647. doi: 10.1001\/archpsyc.64.6.633","journal-title":"Arch Gen Psychiatry"},{"key":"1600_CR15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/appi.ajp.164.7.1061","volume":"164","author":"RSE Keefe","year":"2007","unstructured":"Keefe RSE, Sweeney JA, Gu H et al (2007) Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1061\u20131071. doi: 10.1176\/appi.ajp.164.7.1061","journal-title":"Am J Psychiatry"},{"key":"1600_CR16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"1600_CR17","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","volume":"21","author":"T Lumley","year":"2002","unstructured":"Lumley T (2002) Network meta-analysis for indirect treatment comparisons. Stat Med 21:2313\u20132324. doi: 10.1002\/sim.1201","journal-title":"Stat Med"},{"key":"1600_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4321\/S0213-61632009000200002","volume":"23","author":"G Guilera","year":"2009","unstructured":"Guilera G, Pino O, G\u00f3mez-Benito J, Rojo JE (2009) Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials. Eur J Psychiatry 23:77\u201389. doi: 10.4321\/S0213-61632009000200002","journal-title":"Eur J Psychiatry"},{"key":"1600_CR19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1176\/appi.ajp.161.6.985","volume":"161","author":"RSE Keefe","year":"2004","unstructured":"Keefe RSE, Seidman LJ, Christensen BK et al (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161:985\u2013995","journal-title":"Am J Psychiatry"},{"key":"1600_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biopsych.2005.06.022","volume":"59","author":"RSE Keefe","year":"2006","unstructured":"Keefe RSE, Seidman LJ, Christensen BK et al (2006) Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 59:97\u2013105. doi: 10.1016\/j.biopsych.2005.06.022","journal-title":"Biol Psychiatry"},{"key":"1600_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","volume":"89","author":"ND Woodward","year":"2007","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89:211\u2013224. doi: 10.1016\/j.schres.2006.08.021","journal-title":"Schizophr Res"},{"key":"1600_CR22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neulet.2011.08.027","volume":"503","author":"X Guo","year":"2011","unstructured":"Guo X, Zhai J, Wei Q et al (2011) Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett 503:141\u2013146. doi: 10.1016\/j.neulet.2011.08.027","journal-title":"Neurosci Lett"},{"key":"1600_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.psychres.2010.10.013","volume":"187","author":"R Andersen","year":"2011","unstructured":"Andersen R, Fagerlund B, Rasmussen H et al (2011) Cognitive effects of six months of treatment with quetiapine in antipsychotic-na\u00efve first-episode schizophrenia. Psychiatry Res 187:49\u201354. doi: 10.1016\/j.psychres.2010.10.013","journal-title":"Psychiatry Res"},{"key":"1600_CR24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1076\/clin.13.3.283.1743","volume":"13","author":"MR Basso","year":"1999","unstructured":"Basso MR, Bornstein RA, Lang JM (1999) Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol 13:283\u2013292. doi: 10.1076\/clin.13.3.283.1743","journal-title":"Clin Neuropsychol"},{"key":"1600_CR25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1192\/bjp.bp.106.029009","volume":"192","author":"A Sz\u00f6ke","year":"2008","unstructured":"Sz\u00f6ke A, Trandafir A, Dupont M-E et al (2008) Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 192:248\u2013257. doi: 10.1192\/bjp.bp.106.029009","journal-title":"Br J Psychiatry"},{"key":"1600_CR26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4088\/JCP.08m04634","volume":"70","author":"B Crespo-Facorro","year":"2009","unstructured":"Crespo-Facorro B, Rodr\u00edguez-S\u00e1nchez JM, P\u00e9rez-Iglesias R et al (2009) Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 70:717\u2013729. doi: 10.4088\/JCP.08m04634","journal-title":"J Clin Psychiatry"},{"key":"1600_CR27","doi-asserted-by":"crossref","first-page":"d1199","DOI":"10.1136\/bmj.d1199","volume":"342","author":"D Baldwin","year":"2011","unstructured":"Baldwin D, Woods R, Lawson R, Taylor D (2011) Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 342:d1199","journal-title":"BMJ"},{"key":"1600_CR28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hup.1101","volume":"25","author":"M Riedel","year":"2010","unstructured":"Riedel M, Schennach-Wolff R, Musil R et al (2010) Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol 25:116\u2013125. doi: 10.1002\/hup.1101","journal-title":"Hum Psychopharmacol"},{"key":"1600_CR29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","volume":"57","author":"SE Purdon","year":"2000","unstructured":"Purdon SE, Jones BD, Stip E et al (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 57:249\u2013258","journal-title":"Arch Gen Psychiatry"},{"key":"1600_CR30","first-page":"137","volume":"26","author":"SE Purdon","year":"2001","unstructured":"Purdon SE, Malla A, Labelle A, Lit W (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26:137\u2013149","journal-title":"J Psychiatry Neurosci"},{"key":"1600_CR31","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","volume":"290","author":"R Rosenheck","year":"2003","unstructured":"Rosenheck R, Perlick D, Bingham S et al (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693\u20132702. doi: 10.1001\/jama.290.20.2693","journal-title":"JAMA"},{"key":"1600_CR32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1192\/bjp.bp.108.055137","volume":"194","author":"MJ Cuesta","year":"2009","unstructured":"Cuesta MJ, Jal\u00f3n EG, Campos MS, Peralta V (2009) Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 194:439\u2013445. doi: 10.1192\/bjp.bp.108.055137","journal-title":"Br J Psychiatry"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1600-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1600-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:49:06Z","timestamp":1558687746000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1600-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,22]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1600-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,22]]}}}